Material Event (Form 8-K)

Item 8.01 - Other Events

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity.

On February 17, 2026, Telomir Pharmaceuticals, Inc. (the "Company") announced new preclinical in vitro data evaluating its investigational compound Telomir-1 (Telomir-Zn) in human triple-negative breast cancer ("TNBC") cell lines.

The Company reported that Telomir-Zn reduced viable tumor cell counts across multiple human TNBC models representing biologically distinct molecular subtypes. Specifically:

The Company further reported that the addition of supplemental iron attenuated Telomir-Zn-induced tumor cell mortality across completed models. The Company interprets these findings as supporting an iron-dependent mechanism consistent with previously disclosed intracellular metal-modulating activity.

Two additional TNBC cell lines, BT-549 (mesenchymal-like) and HCC1806 (basal-like), are currently under evaluation.

The Company also referenced prior zebrafish xenograft studies in which Telomir-Zn demonstrated statistically significant reductions in tumor growth and metastasis in select TNBC models.

The Company stated that it is completing additional TNBC subtype evaluations, preparing a TNBC mouse xenograft study in a mammalian system, and continuing IND-enabling activities. As previously disclosed, the Company anticipates submitting an Investigational New Drug (IND) application in the first quarter of 2026.

The Company has previously reported completed IND-enabling GLP safety and toxicology studies in rats and dogs, in which no treatment-related adverse toxicity was observed.